Hansa will receive €110m upfront and a further €5m once the European Medicines Agency accepts Idefirix’s full approval filing.
Idefirix desensitises adult kidney transplant patients with reactive IgG antibodies that could target donated tissues and increase rejection. Credit: sasirin pamai / Shutterstock.com.
SERB Pharmaceuticals has signed an agreement to acquire exclusive development and commercialisation rights to Idefirix (imlifidase) from Hansa Biopharma for a total of €115m ($133.6m).
The deal covers the European Union, Iceland, Liechtenstein, Norway, Switzerland, the UK, and the Middle East and North Africa (MENA) region. Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
